Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...
These drugs are highly effective in treating type 2 diabetes, promoting significant weight loss in obese individuals, and ...
a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (OZEMPIC/WEGOVY®) and tirzepatide ...
The obesity market is undergoing a revolution driven by next-generation GLP-1 therapies ... a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (OZEMPIC ...
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...
News Medical on MSN4d
AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM: An interview with Mina MakerMina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
"Ozempic" and "Mounjaro" are glucagon-like peptide-1 (GLP-1) analogs. The human GLP-1 hormone ... are medications designed to mimic this mechanism to control and treat blood sugar and obesity.
Medpage Today on MSN18h
GLP-1 Agents' Risks and Benefits Broader Than Previously ThoughtGLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback